

## Faster diagnosis of Acute Myocardial Infarction Pocket guide for Elecsys<sup>®</sup> Troponin T-high sensitive

Based on the 2015 NSTE-ACS Guidelines of the European Society of Cardiology



*Test early. Treat right. Save lives.* 

## The first algorithm to rule-in or rule-out AMI within 0 to 1 hour

New in the 2015 European Society of Cardiology (ESC) guidelines

## The 0h/1h algorithm complemented with ESC cut-offs for cTnT-hs<sup>1</sup>



\* Applicable for chest pain patients with onset longer than 3 hours

## Performance to rule-out AMI at admission (0 hour)

Applicable for chest pain patients with onset longer than 3 hours

- In combination with electrocardiogram (ECG) and clinical symptoms, non-ST-segment elevation myocardial infarction (NSTEMI) can be reliably ruled-out with a single value of cTnT-hs < 5 ng/L for chest pain patients with onset longer than 3 hours <sup>1</sup>
- The results of this approach, tested with 18,453 patients, certify a high negative predictive value (NPV) and a low 30-day mortality<sup>2-5</sup>

Reference	N (patients)	Patients ruled-out (%)	NPV	Events in ruled-out patients
Bandstein, N. et al., <i>J Am Coll Cardiol</i> 2014 <sup>2</sup>	14,636	61.0%	99.8%	0.02% (30 - day mortality)
Body, R. et al., <i>Clin Chem</i> 2015 <sup>3</sup>	463	17.3%	100%	0 % (30 - day MACE)
Body, R. et al., <i>Acad Emerg Med</i> 2016 <sup>4</sup>	1,282	36.7%*	99.6 <i>%</i> *	1.3% (30-day MACE)*
Rubini Gimenez, M. et al., Int J Cardio I 2013 <sup>5</sup>	2,072	26.5%	98.4%	0% (30-day mortality)

## Performance of cTnT-hs 0h/1h algorithm

Validated by three multicenter trials in over 3,038 patients



## Early and effective diagnosis of AMI within 0 to 1 hour

More than 75 % of suspected AMI patients triaged within 1 hour<sup>6-8</sup>

#### Adopting the novel 0 h / 1 h algorithm has the potential to:



### When every minute counts

Early diagnosis saves lives in AMI

#### **Test early**

- Number 1 cause of death in the Western world is coronary heart disease<sup>12</sup>
- An early and accurate diagnosis of AMI is critical

#### **Treat right**

- In the 2015 NSTE-ACS ESC guidelines, hs-cTn is now the biomarker test preferred by the ESC. Troponin testing is mandatory in all patients with suspected NSTE-ACS. A rise and/or fall in troponin concentration, in complement with clinical symptoms and ECG, defines AMI<sup>1</sup>
- The time interval to the second cardiac troponin assessment can be shortened to 0 to 1 hour with the use of hs-cTn assays

#### **Save lives**

 Every 30 minute delay between symptoms and treatment increases 1-year mortality by 7.5%<sup>13</sup>

The 0h/1h algorithm using cTnT-hs is endorsed by the 2015 ESC guidelines and allows a highly accurate rapid rule-out and rule-in of AMI, when applied in combination with clinical assessment and 12-lead ECG<sup>1, 6-8</sup>



# of patients triaged within



## Safety aspects of the 0 h/1 h algorithm

*High negative predictive value and low 30-day mortality rate* 



The high NPV (99.1 – 100%) and the low 30-day mortality (0.0 – 0.2%) in the rule-out zone confirm the safety of this approach for early discharge and support the recommendation of the 2015 ESC guidelines<sup>1, 6-8</sup>

## The 0 to 3 hours alternative algorithm to rule-in or rule-out AMI

Confirmed by the 2015 ESC guidelines and based on studies investigating cTnT-hs

#### This algorithm has been established based on studies which mainly investigated cTnT-hs

- This approach requires the use of high sensitivity troponin tests and reduces the observation time from 6 to 3 hours as compared to conventional cTn tests<sup>1</sup>
- It can also be used for patients remaining in the observational zone of the 0 h/1 h algorithm

The recommended cut-off values and minimum  ${\rm \Delta}$  change between 0 and 3 hours:  $^{14,15}$ 

- 7 ng/L (= 50% of the ULN) for values  $\leq$  14 ng/L (the upper limit of normal [ULN], 99<sup>th</sup> percentile of healthy controls corresponding to 14 ng/L for cTnT-hs)<sup>14</sup>
- 20% for values > 14 ng/L
- Higly abnormal cTnT-hs value defined as > 70 ng/L (>5-fold of the ULN)<sup>1</sup>

#### The 0 h/3 h algorithm, complemented with ESC cut-offs for cTnT-hs<sup>1</sup>



GRACE = Global Registry of Acute Coronary Events score; cTnT-hs = Elecsys® cardiac Troponin T high-sensitive; ULN = upper limit of normal, 99<sup>th</sup> percentile of healthy controls. Delta change dependent on assay.

## Point Of Care option with Roche cobas® h 232 system

Immediate rule-in for high-risk AMI patients with initial sample

- Easy to use even in mobile situations and ensures fast turn-around time with results available in just 12 minutes<sup>16,17</sup>
- POC cTnT  $\geq$  50 ng/L can be used to identify patients with a high risk of long-term mortality for accelerated medical investigation and appropriate treatment<sup>16</sup>

cobas h 232

- Pre-hospital patients with suspected AMI with Roche CARDIAC POC Troponin T ≥ 50 ng/L have a 3-10 times higher long-term mortality risk<sup>16</sup>
- Specificity for the diagnosis of AMI (POC cTnT  $\geq$  50 ng/L); 95%, PPV: 68%  $^{16}$

Roche CARDIAC POC Troponin T test ≥ 50 ng/L allows fast triaging in every setting

## Standardized Troponin T results among all locations

From pre-hospital and emergency rooms to laboratories



- 1. Roffi, M. et al. (2016). Eur Heart J 37(3), 267-315.
- 2. Bandstein, N. et al. (2014). J Am Coll Cardio 63(23), 2569 -78.
- 3. Body, R. et al. (2015). Clin Chem 61(7), 983 9.
- 4. Body, R. et al. (2016). Acad Emerg Med 23(9), 1004-13.
- 5. Rubini-Giménez, M. et al. (2013). Int J Cardiol 168(4), 3896 901.
- 6. Reichlin, T. et al. (2012). Arch Intern Med 172(16), 1211 8.
- 7. Reichlin, T. et al. (2015). CMAJ 187(8), E243 52.
- 8. Mueller, C. et al. (2016). Ann Emerg Med (68)1, 76 87.
- 9. Eggers, KM. et al. (2016). Eur Heart J 37(30), 2417 24.
- 10. Twerenbold, R. et al. (2016). Eur Heart J 37(44), 3324 3332.
- 11. Ambavane, A. et al. (2017). Plos One, 12(11), e0187662.
- 12. Roger, L.V. (2007). Med Clin North Am 91(4), 537 52.
- 13. De Lucca, G. et al. (2004). Circulation 109(10), 1223 5.
- 14. Saenger, AK. et al. (2011). Clin Chem Acta 412(9-10), 748 54.
- 15. Thygessen, K. et al. (2012). Eur Heart J 33(18), 2552 -7.
- 16. Stengaard, C. et al. (2013). Am J Cardiol 112(9),1231-8.
- 17. Roche CARDIAC POC Troponin T Package Insert, 2015.

Roche Diagnostics International Ltd CH-6343 Rotkreuz Switzerland

© 2018

All trademarks mentioned enjoy legal protection. www.roche.com

Not for distribution in the USA.